FDA Peptide Ruling 2026: What Changed and What It Means for You

Your compounded semaglutide prescription might be gone by fall. Your BPC-157, though? It could be legal to compound again by August. Two very different things happened in April 2026, and most coverage is mashing them together into one confusing headline. Here's the split: the FDA is closing the door on compounded GLP-1s while simultaneously reopening it for a dozen peptides that got yanked in 2023. What you do in the next 90 days depends entirely on which compounds you're using.

Key Takeaways

• The FDA proposed on April 30, 2026 to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, closing the last federal pathway for large-scale GLP-1 compounding.
• On April 15, 2026, the FDA moved 12+ peptides (BPC-157, TB-500, KPV, MOTS-c, and others) out of Category 2 ("significant safety concerns") and into active review for possible re-approval for compounding.
• The PCAC hearing on July 23-24, 2026 will evaluate 7 peptides for the 503A bulks list. GHK-Cu (non-injectable) has a separate hearing scheduled by February 2027.
• Brand-name semaglutide (Ozempic/Wegovy) runs $900-1,350/month without insurance in 2026. Compounded versions were $150-350/month. That gap is about to become unavoidable for anyone on GLP-1s.
• If you're on compounded peptides, confirming whether your pharmacy is 503A or 503B determines whether your supply survives the next 6 months.

---

What the FDA Actually Did in April 2026

Two separate regulatory actions dropped within two weeks of each other, and they move in opposite directions.

Action 1 (April 15, 2026): The FDA updated the 503A bulk drug substances list, pulling more than a dozen peptides out of Category 2. Category 2 is the "raises significant safety concerns" bucket that effectively banned compounding pharmacies from using these substances. Getting removed from Category 2 doesn't mean they're approved. It means the FDA is actively reviewing them for possible inclusion on the 503A bulks list, which would make them legal to compound again with a valid prescription.

Action 2 (April 30, 2026): The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding "no clinical need" for outsourcing facilities to compound these drugs from bulk substances. This is the permanent kill shot for large-scale GLP-1 compounding.

Different mechanisms. Different timelines. Different drugs. Different outcomes. The peptide door is cracking open. The GLP-1 door is being welded shut.

The distinction matters because each group runs through a different section of the Federal Food, Drug, and Cosmetic Act. Section 503A governs traditional compounding pharmacies that fill patient-specific prescriptions. Section 503B governs outsourcing facilities that compound at scale. The peptide review is a 503A process. The GLP-1 exclusion targets 503B. If you're confused, you're supposed to be. This system was not designed for patients to navigate easily.

---

GLP-1 Compounding Is Being Shut Down: The Full Timeline

The crackdown didn't start in April 2026. It started in October 2024, and every legal challenge since then has failed.

October 2024: The FDA declared the tirzepatide shortage resolved. The Outsourcing Facilities Association (OFA) and FarmaKeio Custom Compounding sued the same day in the Northern District of Texas, arguing the decision was arbitrary.

February 18, 2025: FDA's enforcement discretion window for 503A pharmacies compounding tirzepatide expired. State-licensed pharmacies could no longer compound tirzepatide copies.

March 5, 2025: Judge Mark Pittman denied OFA's motion for a preliminary injunction, ruling in the FDA's favor. The court also denied the request for a stay of the FDA's shortage-resolved declaration.

March 10, 2025: OFA filed a notice of interlocutory appeal to the Fifth Circuit.

March 19, 2025: FDA's enforcement discretion for 503B outsourcing facilities expired. Both pharmacy types lost their compounding window for tirzepatide.

2025 (various dates): Semaglutide also removed from the drug shortage list, triggering similar enforcement deadlines.

April 30, 2026: FDA proposed permanently excluding all three GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) from the 503B bulks list.

Both legal pathways are closing at the same time. The shortage list removal killed the immediate exemption. The bulks list exclusion, if finalized, kills the long-term one. Even if a future shortage occurs, a finalized exclusion from the bulks list would mean 503B facilities still couldn't compound these drugs. The OFA appeal to the Fifth Circuit remains pending, but no injunction is in place, and the FDA has been enforcing continuously.

If you're currently getting compounded semaglutide or tirzepatide, this is not a temporary pause. It's the regulatory endgame.

---

BPC-157, TB-500, GHK-Cu: Which Peptides Are Coming Back

While GLP-1 access contracts, the peptide picture is genuinely exciting. Between late 2023 and December 2024, the FDA moved 19 popular peptides into Category 2 on the 503A list, flagging them for "significant safety concerns." That designation effectively froze legal compounding.

On April 15, 2026, the FDA reversed course on more than a dozen of those peptides, pulling them out of Category 2 and scheduling them for formal review. Like most research peptides, these compounds aren't FDA-approved drugs, which is exactly why the interesting real-world evidence lives in what women are actually reporting and what the early mechanistic data suggests. The removal from Category 2 signals the FDA found the safety-concern designation wasn't warranted enough to keep them frozen.

Here's where things stand:

The July 23-24, 2026 PCAC (Pharmacy Compounding Advisory Committee) hearing is the big one. Seven peptides go before the committee for evaluation. If the PCAC recommends inclusion on the 503A bulks list and the FDA agrees, compounding pharmacies with valid prescriptions could legally prepare these peptides again.

GHK-Cu has a weird path. The nominator withdrew the injectable route, so injectable GHK-Cu is off the table for now. But non-injectable GHK-Cu for women over 40 was re-added to Category 1 on May 5, 2026, after the nominator clarified they only intended to withdraw the injectable nomination. The FDA has announced it intends to consult the PCAC on non-injectable GHK-Cu by February 2027.

Women on BPC-157 and TB-500 protocols consistently report faster recovery from soft tissue injuries, reduced joint inflammation, and improved gut healing. The early peptide research on BPC-157's angiogenic and anti-inflammatory mechanisms is genuinely promising, and the PCAC review means the FDA is taking the clinical interest seriously enough to evaluate rather than just restrict.

Not every peptide made the cut. CJC-1295, Ipamorelin, and Melanotan II remain in Category 2 with no hearing scheduled. If you're using those, the access picture hasn't changed.

---

503A vs. 503B: Why Your Pharmacy Type Determines Your Access

This is the part that trips everyone up, and it's the single most important thing to know right now.

503A pharmacies are traditional compounding pharmacies licensed by your state. They fill individual prescriptions from a specific provider for a specific patient. Your neighborhood compounding pharmacy is almost certainly 503A. They're smaller, and they compound one prescription at a time based on a doctor's order.

503B outsourcing facilities are registered with the FDA and compound at scale. They don't need individual prescriptions. They can produce large batches and ship them to hospitals, clinics, and providers for office use. Think mini-manufacturers with a compounding exemption. Companies like FarmaKeio, Empower Pharmacy, and similar large operations are 503B facilities.

Here's why this distinction controls your access in 2026:

The GLP-1 exclusion proposal specifically targets 503B. But 503A pharmacies already lost their compounding window for tirzepatide when enforcement discretion expired in February 2025, and semaglutide followed. So for GLP-1s, both pathways are effectively closed or closing.

For peptides, the story flips. The PCAC review in July 2026 is a 503A process. If BPC-157, TB-500, and the other six peptides get approved for the 503A bulks list, your local compounding pharmacy can fill those prescriptions again. 503B facilities would need separate approval through the 503B bulks list process.

Call your pharmacy. Ask if they're 503A or 503B. That one question tells you which regulatory track applies to your prescriptions.

---

What This Means for Your Current Prescriptions and Costs

If you're on compounded GLP-1s, the math just got brutal. If you're on compounded peptides, it's a waiting game with a real deadline.

GLP-1 cost impact:

Compounded semaglutide was running $150-350/month through 503B outsourcing facilities in 2024-2025. Brand-name alternatives in 2026:

That's a $600-1,000/month increase for women who were on compounded GLP-1s and don't have insurance coverage. Novo Nordisk and Eli Lilly both have savings programs, but eligibility requirements are restrictive, and most exclude patients with commercial insurance that covers the drug at any level. For a deeper breakdown of what women actually pay across routes, see our peptide therapy cost guide.

Peptide cost impact:

Harder to predict because it depends entirely on PCAC outcomes. If BPC-157 and TB-500 return to the 503A bulks list, compounding pharmacies will be able to prepare them again. Historically, compounded BPC-157 ran $100-200/month for injectable protocols, and topical GHK-Cu preparations were $40-120/month depending on concentration and pharmacy.

If the PCAC review goes well and these peptides get 503A approval, prices should return to pre-restriction levels. Compounding pharmacies have been sitting on the demand data for two years. They're ready to fill prescriptions the moment the regulatory green light comes.

If the PCAC doesn't approve them, the access picture stays frozen, and women who want these peptides will continue working with peptide-literate providers who know how to navigate the current landscape.

---

How to Keep Access: Your Moves Before July 2026

You have about 60 days before the PCAC hearing and an open comment period on the GLP-1 exclusion. Here's what to do with that time.

1. Find out if your pharmacy is 503A or 503B. Call them. The front desk can tell you. If you're getting compounded GLP-1s from a 503B facility, your supply is at direct risk. If you're getting peptides from a 503A pharmacy, your access depends on the July PCAC outcome.

2. Talk to your prescriber about continuity. If you're on compounded semaglutide, ask your doctor or telehealth provider what their plan is for transitioning patients to brand-name GLP-1s. Good providers are already building this into their practice. Ask specifically about manufacturer savings programs, prior authorization support, and whether they'll help you apply.

3. Submit a public comment on the 503B exclusion proposal. The FDA's proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list has a public comment period. Patient comments carry weight, especially when they describe specific clinical situations where compounded access mattered. The comment portal is on the Federal Register notice. Comments about cost barriers, insurance denial, and clinical outcomes are the most useful.

4. If you're using BPC-157, TB-500, or other peptides under review, ask your provider about the PCAC timeline. The July 23-24 hearing will evaluate these peptides for 503A inclusion. Your provider should know whether they plan to resume prescribing if approval comes through. If they don't know what PCAC is, that tells you something about how peptide-literate they actually are.

5. Look at telehealth providers that are already pivoting. Several telehealth platforms that built their business on compounded GLP-1s are now transitioning to brand-name prescribing with insurance navigation support. Others are expanding their peptide offerings in anticipation of PCAC approvals. The provider landscape is shifting fast.

---

Where to Get GLP-1s and Peptides Now: Provider Options Compared

The access routes look different depending on what you're trying to get.

For GLP-1s, the play is straightforward: find a provider who will prescribe brand-name and help you fight for insurance coverage. The telehealth platforms that used to offer compounded versions are rapidly adding insurance support services because they see the same writing on the wall. If you're weighing tirzepatide vs semaglutide, that decision now happens entirely within the brand-name landscape.

For peptides, the play is finding a provider who actually understands these compounds, knows the regulatory timeline, and is positioned to prescribe the moment PCAC clears them. A good peptide-prescribing provider will ask about your health history, current medications, and specific goals. They'll want bloodwork before starting (CBC, metabolic panel, inflammatory markers at minimum). They won't just hand you a vial.

[Compare peptide and GLP-1 providers now →]

---

FAQ

Can I still get compounded semaglutide in 2026? As of May 2026, compounded semaglutide is extremely difficult to obtain legally. Semaglutide was removed from the drug shortage list in 2025, and the FDA proposed on April 30, 2026 to permanently exclude it from the 503B bulks list. Some 503A pharmacies may still have limited inventory, but new compounding is effectively over unless the OFA appeal succeeds or the exclusion proposal is withdrawn.

Is compounded tirzepatide permanently banned? Functionally, yes. FDA enforcement discretion expired for 503A pharmacies in February 2025 and for 503B facilities in March 2025. The April 30, 2026 proposal to exclude tirzepatide from the 503B bulks list would make this permanent. The OFA v. FDA appeal is pending in the Fifth Circuit, but no injunction is in place.

What happens to my current compounded GLP-1 prescription? If your pharmacy is 503B, they cannot legally compound new GLP-1 prescriptions without a shortage-list or bulks-list basis. Any remaining supply is from existing inventory. Talk to your prescriber about transitioning to brand-name Ozempic, Wegovy, or Zepbound. Ask about manufacturer savings programs and insurance prior authorization.

Is BPC-157 legal to get from a compounding pharmacy right now? BPC-157 was removed from Category 2 on April 15, 2026 and is scheduled for PCAC review on July 23, 2026. During the interim review period, compounding pharmacies are operating under the FDA's interim policy for substances under evaluation. Some 503A pharmacies are compounding BPC-157 during this period; ask your provider and pharmacy directly about their interpretation of the interim policy.

What is the PCAC hearing in July 2026 and will it affect my peptides? The Pharmacy Compounding Advisory Committee (PCAC) meets July 23-24, 2026 to evaluate seven peptides (BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax, and Epitalon) for possible inclusion on the 503A bulks list. If the committee recommends inclusion and the FDA agrees, licensed compounding pharmacies could legally compound these peptides with a valid prescription. This is the single most important regulatory event for peptide access in 2026.

Can my doctor still prescribe GHK-Cu for topical use? Non-injectable GHK-Cu was re-added to Category 1 on May 5, 2026, after the nominator clarified it only withdrew the injectable nomination. The FDA plans to consult the PCAC on non-injectable GHK-Cu by February 2027. During this review period, topical GHK-Cu compounding is in a more favorable position than injectable. Your provider can prescribe it, and a 503A pharmacy should be able to compound topical formulations under the interim policy.

What's the difference between a 503A and 503B pharmacy? A 503A pharmacy is a state-licensed compounding pharmacy that fills individual, patient-specific prescriptions. A 503B outsourcing facility is FDA-registered and compounds at scale without needing individual prescriptions. The GLP-1 exclusion proposal targets 503B facilities. The peptide PCAC review is a 503A process. Call your pharmacy and ask which they are.

How much more will I pay for brand-name Ozempic vs. compounded semaglutide? Compounded semaglutide was $150-350/month. Brand-name Ozempic runs $900-1,000/month and Wegovy runs $1,300-1,350/month without insurance in 2026. With commercial insurance that covers it, copays range from $0-50/month. Manufacturer savings cards can bring costs to $500-550/month for eligible patients. That's a $600-1,000/month increase for the uninsured.

Can I stock up on compounded peptides before the ruling takes effect? Compounding pharmacies fill prescriptions, not bulk orders. Your provider writes a prescription for a specific course of treatment, and the pharmacy fills it. You can't order six months of supply in advance. What you can do is establish a relationship with a peptide-prescribing provider now, so you're positioned to get prescriptions filled quickly if PCAC approval comes through in late July or August 2026.

Will the OFA v. FDA lawsuit change anything for compounded GLP-1 access? The OFA filed an interlocutory appeal to the Fifth Circuit after losing at the district level in March 2025. No injunction is currently in place, meaning the FDA is actively enforcing. Even if OFA wins on the shortage-list question, the separate 503B bulks list exclusion (proposed April 30, 2026) would still close the compounding pathway independently. The lawsuit is a long shot for restoring broad access.

Are peptides like Ipamorelin and CJC-1295 still banned for compounding? Yes. CJC-1295, Ipamorelin Acetate, and Melanotan II remain in Category 2 with no PCAC hearing scheduled. The April 2026 removals did not include these peptides. If you're using them, the regulatory picture has not improved, and there's no timeline for review.

Not sure which peptides or protocols actually fit your situation given all these changes? Build your personal plan — it accounts for the current regulatory landscape and what's actually accessible right now.